Abstract Library

#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?

Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,

Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,

#2738 Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

Introduction: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. Due to its low incidence and wide tissue distribution few representative preclinical models are available

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tesselaar M

Authors: Dijkstra K, van den Berg J, Weber F, van de Haar J, Velds A,

Keywords: organoids, gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), disease modeling, pre-clinical models,

#1781 Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis

Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Grigorescu R, Stanel I, Gramaticu I, Dinu I, Buica F,

Keywords: GEP-NEC, chemotherapy, prognostic factors,

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: IBRAHIM T

Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,

Keywords: GEP-NEC,chemotherapy,